Scleroderma Clinical Trial
Official title:
High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma)
Verified date | October 2015 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of
presentation, and course. The natural history of this chronic autoimmune disease ranges from
benign to fatal. Patients are classified into limited and diffuse scleroderma defined by the
degree of skin involvement. Patients with limited disease (e.g. the C.R.E.S.T. syndrome)
generally have mild disease and normal survival. However, patients with diffuse cutaneous
scleroderma often have severe multi-system disease that is not only devastating emotionally
and physically but is associated with a 60-70% five year survival and a 40-50% 10 year
survival. No therapies have proven effective in the treatment of scleroderma. Strategy to
treat scleroderma have included attempts to prevent fibrosis with drugs that interfere with
collagen metabolism, attempts to modify the disease process by immunosuppression and
attempts to alter the disease by vasoactive drugs. High dose of corticosteroids and other
immunosuppressive drugs (e.g. chlorambucil, 5-fluorouracil, methotrexate, cyclophosphamide,
cyclosporine) used at conventional doses have not proven curative, but have shown some
benefit for inflammatory features of the disease (e.g. arthritis, myositis, fibrosing
alveolitis).
Both allogeneic and autologous bone marrow transplantation (BMT) have shown to modify and in
some instances reverse a variety of animal models of autoimmune disease. This has prompted
many investigators to propose the use of peripheral blood stem cell transplantation (PBSCT)
for the treatment of autoimmune disease including scleroderma. Unfortunately, this approach
risks infusing untreated autoreactive lymphocyte clones after the immunoablative preparative
regimen. We have previously demonstrated that high-dose cyclophosphamide without BMT can
induce durable and complete remissions in another autoimmune disease, severe aplastic
anemia. Recent data with high dose cyclophosphamide show that it can induce complete
remissions in other autoimmune hematologic disorders. The objective of this study is to
determine whether high dose cyclophosphamide can induce a durable remission in scleroderma
patients with life-threatening disease, and to determine toxicity of high dose
cyclophosphamide in high risk scleroderma patients.
Status | Completed |
Enrollment | 6 |
Est. completion date | May 2010 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Meet established criteria for a diagnosis of diffuse cutaneous scleroderma and have evidence of moderately severe organ damage and clinical evidence of active disease. - Patients with diffuse scleroderma who have evidence of active fibrosing alveolitis manifested by either a greater than 10% decline in the forced vital capacity or the diffusing capacity from the defined normal values or from baseline measurements. - Patients with severe deforming localized scleroderma (generalized morphea, liner morphea, keloid or bullous scleroderma) that threatens their capacity to function normally in society. Exclusion Criteria: - Age less than 18 years and over 70 years - Any risk of pregnancy - Cardiac ejection fraction of < 45% - Serum creatinine > 3.0 - Patients who are pre-terminal or moribund - Bilirubin > 2.0, transaminases > 2x normal - FVC, FEV1 (5/30/01) < 50% predicted |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Primary Endpoint Will be an Improvement in the Modified Rodnan Skin Score. | The modified Rodnan skin score is the accepted clinical measure of scleroderma skin activity. The investigator will assess the thickening of the skin using the modified Rodnan skin score through simple palpation on 17 different body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Skin thickness is assessed on a scale of 0-3; 0 representing normal skin and 3 being severe thickening. The sum of the individual scores can range from 0-51; 0 (normal) to 51 (severe thickening in all 17 areas) A 25% improvement in the modified Rodnan Skin score will be considered significant at any time point in the study. Modified Rodnan Skin Score was evaluated at months 0,1,3,6,12 and 24 months. | 0 to 24 months | No |
Secondary | Secondary Endpoint Was Changes in the Total Severity Score (Composite) and Measures of Severity in Each Specific Organ (Organ Specific Measures). | The total severity score is comprised of results from the Health Assessment Questionnaire-Disability Index (HAQ-DI) a 48 item questionnaire assessing ability to perform activities of daily living, use of assistive devises and a 6 item analog scale of pain severity from 0 cm (no pain) to 14.3 cm (very severe pain). The physician global assessment (PGA) which is a visual analogue scale from 0 to 100 on which the physician rates the patient's disease severity based on their observations. The score also included the Forced Vital Capacity (FVC) which is a measure of lung capacity and Diffusing Capacity (DLCO) which measures the ability of the lung to absorb oxygen accross the membrances in the alveoli. The FVC and DLCO are measured through pulmonary function testing. The predicted lung volumes were referenced from NHANES/Hanikson et al and for DLCO predicteds were from Knudson. Pre and post study intervention scores were compared. | 0-24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT02915835 -
Riociguat in Scleroderma Associated Digital Ulcers
|
Phase 2 | |
Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|